Marlow, UK (ots) – Am 23. September wurde BOTOX® (Botulinumtoxin Typ A) von Allergan durch das Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) in Deutschland zugelassen für die Behandlung der Harninkontinenz bei Erwachsenen mit neurogener Detrusorhyperaktivität bei neurogener Blase infolge einer stabilen subzervikalen Rückenmarksverletzung oder Multipler Sklerose (MS). Die Zulassung gilt ausschließlich für BOTOX® und stellt [...]
Tag Archive > Efficacy
Amira Pharmaceuticals stellt präklinische und klinische Daten aus seinem DP2-Rezeptor-Antagonistenprogramm auf der Pacifichem 2010 vor
San Diego (ots/PRNewswire) – Amira Pharmaceuticals, Inc. kündigte heute an, dass das Unternehmen präklinische und klinische Daten aus seinem DP2-Rezeptor-Antagonistenproramm am 17. Dezember 2010 auf der Pacifichem 2010 in Honolulu im US-Bundesstaat Hawaii vorstellen wird. Die Daten aus Amiras DP2-Program im klinischen Stadium werden von Brian Stearns, Ph.D., im Rahmen einer Präsentation mit dem Titel [...]
Positive Resultate der LigoCyte Norovirus Vaccine Challenge Study wurden auf der IDSA-Jahresversammlung vorgestellt
Bozeman, Montana (ots/PRNewswire) – LigoCyte Pharmaceuticals, Inc., ein biopharmazeutisches Privatunternehmen , das sich mit klinischen Studien und Entwicklungen von innovativen Impfstoffen befasst, kündigte heute positive Ergebnisse aus der Phase I/II der Herausforderungsstudie seines Norovirus Virus-Like Particle (VLP) Impfstoffkandidaten an. Dr. med. Robert Atmar vom Baylor College of Medicine, der Leiter der Studie teilte die Studiendaten [...]
Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound / Anti-VEGF PRS-050 is first Anticalin tested in humans
Freising-Weihenstephan (ots) – Pieris AG announced today the initiation of a Phase I clinical trial in cancer patients for its lead program, PRS-050, an anti-VEGF Anticalin. The trial is an open-label, dose-escalating evaluation of the compound’s safety and tolerability in patients with solid tumors. Conducted at three sites in Germany, the trial is underway and [...]
NEVO(TM) Sirolimus-Eluting Coronary Stent Continues to Demonstrate Excellent Safety and Efficacy Outcomes in New Twelve-Month Data
Paris, May 25, 2010 (ots/PRNewswire) – At 12 months the NEVO(TM) Sirolimus-eluting Coronary Stent has continued to demonstrate excellent safety and efficacy outcomes compared to Taxus(R) Liberte(R) according to new data presented today from the NEVO(TM) RES-I clinical trial. These results were presented as a late breaking trial at EuroPCR, the leading medical conference in [...]
SYGNIS announces nine months results of fiscal year 2009/2010
Heidelberg (ots) – SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard) today reports financial results for the third quarter and the first nine months of the fiscal year 2009/2010 ended December 31, 2009. Financials – Cash including marketable securities amounted to EUR16.4 million as of December 31, 2009 (EUR26.0 million Q3 2008/2009). Long term [...]
EANS-News: Intercell starts an additional efficacy trial for its patch-based investigational Travelers´ Diarrhea Vaccine System in Asia
——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Research & Development Wien (euro adhoc) – _ » Phase II pilot efficacy trial – placebo controlled field study to evaluate efficacy and enterotoxigenic E. coli (ETEC) incidence of vaccinated European travelers to India » Study [...]
Gartner Says 2009 and 2010 Will Be the Years to Make or Break a Career in IT
(pressebox) Cannes, France, 04.11.2009, As organisations begin to prepare for a return to business growth, many are finding themselves at a major crossroads at which they must decide whether to remain on their longstanding current path of performing IT activities or to go in a different direction, according to Gartner, Inc. Organisations that opt for [...]
Superior Efficacy-dose Ratio for Lantus(R) Over detemir
Paris (ots/PRNewswire) – – 76% Higher Dose of Insulin detemir Needed to Achieve Similar, Well Tolerated Glycemic Control Versus Lantus(R) Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today results of a head-to-head study providing further evidence on the efficacy of once-daily, 24-hour basal insulin Lantus(R) (insulin glargine [rDNA] injection) compared to twice-daily insulin detemir. The [...]
Microsoft Corporation and Vivaki/Publicis Groupe Announce Broad Strategic Agreement
Paris and Redmond, Washington (ots/PRNewswire) – – Companies Pursue More Engaging Digital Content, Increased Marketing Performance and Sharply-Defined Audiences Microsoft and Publicis Groupe today announced a broad agreement to closely cooperate on three core objectives enabled by the emergence of the digital media world. Focusing on Content, Performance and Audience, respective teams will work to [...]
Stable F&E Budgets help Biotech Suppliers Defy the Crisis
(pressebox) Berlin, 16.06.2009, Several American pharmaceutical giants such as Pfizer, Johnson & Johnson or Merck & Co are currently fighting losses in sales and a lack of upcoming products. In Europe, Sanofi-Aventis and GlaxoSmithKline are affected. However, not all pharmaceutical companies are suffering from the crisis. According to the assessment of many analysts, Roche, Novartis [...]
Enbrel(R) Receives Positive European Recommendations for a New Plaque Psoriasis Treatment Regimen and New Pre-Filled Pen Delivery Device
Maidenhead, England (ots/PRNewswire) – – CHMP Recommends Approval of a Continuous Dosing Regimen Option for Enbrel In Plaque Psoriasis, and a New Pre-Filled Pen Delivery Device Today, Wyeth received positive recommendations from the European Committee for Medicinal Products for Human Use (CHMP) for two recent submissions relating to Enbrel(R) (etanercept), the tumour necrosis factor alpha [...]
IT Experts say start preparing now for Office 2000 security patch service withdrawal from July 14
(pressebox) San Mateo, CA, 01.06.2009, 1st June 2000 Fortify Software, the application vulnerability specialist, is warning companies to take action now and prepare for Microsoft’s withdrawal of its security update service for Office 2000 from July 14 onwards this year. "That date is, of course, Patch Tuesday, so Office 2000 users can expect their last [...]
Ym Biosciences Provides Eu Regulatory Update
(pressebox) Mississauga, Ontario, 05.12.2008 – YM BioSciences Inc. (NYSE Alternext US:YMI, TSX:YM, AIM:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today reported that Oncoscience AG, the European licensee of nimotuzumab from YM’s subsidiary, CIMYM BioSciences Inc., has withdrawn its application to the European Medicines Agency (EMEA) for marketing authorization [...]
centrotherm photovoltaics concludes current share repurchase program
——————————————————————————– ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement. ——————————————————————————– shares Blaubeuren (euro adhoc) – November 24, 2008 – centrotherm photovoltaics AG has concluded the current share repurchase program on schedule. The program entailed the repurchase of up to 128,014 shares. A total of 128,014 shares were repurchased [...]
